Hao-Fountain Syndrome: 32 novel patients reveal new insights into the clinical spectrum

Updating the clinical spectrum of HAFOUS

Moritz Claudius Wimmer[1] (moritz.wimmer@med.uni-heidelberg.de),
Heiko Brennenstuhl[1] (heiko.brennenstuhl@med.uni-heidelberg.de),
Steffen Hirsch[1] (steffen.hirsch@med.uni-heidelberg.de),
Laura Dötsch[1] (laura.doetsch@med.uni-heidelberg.de),
Samy Unser[1] (samy.unser@med.uni-heidelberg.de),
Pilar Caro[1] (MariadelPilar.CaroMartin@med.uni-heidelberg.de),
Christian Patrick Schaaf[1,2] (christian.schaaf@med.uni-heidelberg.de)

[1]Institute of Human Genetics, Heidelberg University, Heidelberg
[2]Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

Correspondence:
Christian Patrick Schaaf, Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, D-69120 Heidelberg, Germany
christian.schaaf@med.uni-heidelberg.de

Ethical statement:
This study was performed under the research protocol H-34578, approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals. All individuals and their guardians were informed and provided consent for the study.

Statement of contribution:
Methodology: MCW, HB; Investigation: MCW, LD, PC; Validation: SH, SU; Project administration: MCW, PC; Writing – original draft: MCW; Writing – review and editing: CPS, MCW; Visualization: HB, MCW; Supervising: CPS

Acknowledgments:
The authors thank the individuals and the families with Hao-Fountain syndrome, who have provided clinical data and overwhelming support for our efforts. The authors also thank Ferdinand Althammer and Jannis Bücking for comments that greatly improved the manuscript.

Conflicts of interest:
The authors declare no competing interests.

Data Availability statement:
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Abstract

Hao-Fountain syndrome (HAFOUS, OMIM: #616863) is a neurodevelopmental disorder caused by pathogenic variants in the gene *USP7* coding for USP7, a protein involved in several crucial cellular homeostatic mechanisms and the recently described MUST complex. The phenotype of HAFOUS is insufficiently understood, yet there is a great need to better understand the spectrum of disease, genotype-phenotype correlations, and disease trajectories.

We now present a larger cohort of 32 additional individuals and provide further clinical information about six previously reported individuals. A questionnaire-based study was performed to characterize the phenotype of Hao-Fountain syndrome more clearly, to highlight new traits, and to better distinguish the disease from related neurodevelopmental disorders. In addition to confirming previously described features, we report hyperphagia and increased body weight in a subset of individuals. HAFOUS patients present an increased rate of birth complications, congenital anomalies, and abnormal pain thresholds. Speech impairment emerges as a potential hallmark of Hao-Fountain syndrome. Cognitive testing reports reveal borderline intellectual functioning on average, although some individuals score in the range of intellectual disability.

Finally, we created a syndrome-specific severity score. This score neither indicates a sex- nor age-specific difference of clinical severity, yet highlights a more severe outcome when amino acid changes colocalize to the catalytic domain of the USP7 protein.

Keywords

USP7, Hao-Fountain syndrome, neurodevelopmental disorder, rare disease, clinical spectrum, genotype-phenotype association

Introduction

Ubiquitin-specific protease 7 (USP7), also known as Herpesvirus-associated protease (HAUSP), plays a crucial role as a regulator of ubiquitination in genome stability pathways[1]. Recently, it was also described to contribute to the MUST pathway, which regulates intracellular protein trafficking and recycling[2,3]. Another protein involved in this pathway, MAGEL2, is associated with Schaaf-Yang (SYS, OMIM #615547)[4] and Prader-Willi syndromes (PWS, OMIM #176270)[5], and USP7 haploinsufficiency was subsequently shown to also cause a neurodevelopmental disorder[3,6]. The initial report included seven individuals, six cases with genomic deletions containing the *USP7* gene and one individual with a *USP7* nonsense mutation[3]. Patients presented with developmental delay (DD), autism spectrum disorder (ASD), seizures, a behavioral phenotype, and signs of hypogonadism. Intriguingly, this clinical presentation shows great overlap with PWS and SYS by neurodevelopmental delay, failure to thrive, endocrine disruptions, behavioral anomalies, and muscular hypotonia[5,7-9].

To date, the largest cohort of patients affected by Hao-Fountain Syndrome (HAFOUS, OMIM: #616863) was presented by Fountain et al. in 2019 describing 16 novel patients[6]. The consistency of symptoms, regardless of the underlying variant type, supported the concept of USP7 haploinsufficiency as the causal factor of the disorder. Individuals presented with DD/ID, eye anomalies, feeding difficulties, GERD, behavioral anomalies, and ASD as the most frequent features. Furthermore, an in-depth secondary analysis of brain MRI images revealed various morphological anomalies with white matter paucity as the most frequent finding, reflected by a significant reduction of thickness of both splenium and body of the corpus callosum[6].

In subsequent case reports, six more patients were added to the publicly available cohort[10-13]. These new cases implicate a higher variability of the clinical spectrum, as fetal complications[10,11], congenital heart defects[10], and isolated tubal torsion[12] were first described. Next to these specific items, the clinical presentation of these patients is mainly according to the phenotype described previously.

We here present 32 novel individuals with variants in *USP7* and provide further clinical information about six previously described patients with a first report on intellectual functioning, growth parameters, and pregnancy complications. Finally, by creating a severity score of clinical phenotype, we provide an outline of genotype-phenotype correlations.

Subjects and Methods

This study is based on a 12-page questionnaire sent to all families listed in the USP7 registry. This registry was built in cooperation with the Foundation for USP7-related Diseases (www.USP7.org), enrolment was based on genotype. We included all individuals with confirmed genetic variants affecting the *USP7* gene and categorized patients based on type of mutations. Variants, including cases from the literature, were standardized using Mutalzyer 3 (https://mutalyzer.nl) and re-classified according to the AMP/ACMG criteria[14]. The questionnaire used within this study was designed with the Foundation for USP7-related Diseases to capture previously unrecognized symptoms. It was conceived to be filled out by the parents and always contained the option to select "unknown" if reporting was

impossible. Growth centiles and z-scores were calculated using an online tool based on CDC standard values (https://www.pedz.de/en). Detailed clinical reports were requested, especially brain imaging and EEG reports. The data presented in this study are primarily based on parental reports. We endeavored to enhance the validation process by incorporating clinical reports whenever feasible. It should be noted that results from testing reports, radiological imaging reports, and behavioral assessments were accepted without secondary evaluation. Thirty-eight families replied to the request and sent back at least the questionnaire and a genetic testing report, accompanied by a consent form. Six of those patients had been previously reported by Fountain et al. in 2019[6]. We labeled the cases based on their chronological appearance in the literature and therefore report individuals #30 to #61 (*Supplemental table 1*).

If not stated otherwise, the frequency of the symptoms always describes the prevalence in all publicly accessible cases, including patients described by Hao et al., Fountain et al., Capra et al., Zampieri et al., Zheng et al., and the participants of this study[3,6,10,12,13].

A severity score was developed based on the most frequently occurring clinical features. Where available, the score considers the range of severity, e.g., one or two points based on the severity of the developmental delay. A scale of 0 to 24 points was assigned and normalized afterwards to avoid bias by data availability. The exact procedure next to the calculation of individual severity scores can be seen in the supplemental material (*supplemental methods, supplemental table 14*). Severity scores were calculated exclusively for participants of our study. The categorization of patients with a missense variant, as described below, was conducted based on the protein domain boundaries outlined by Valles et al. in 2020[1].

Differences between two groups for the severity index were evaluated using Student's t test. Whenever comparing more than one group for continuous variables (developmental milestones, growth parameters), a one-way ANOVA analysis was performed. One-sample t tests were performed in a z-normalized setting to assess deviation from the average population. Analyses were conducted using GraphPad (Version 9.5.1) or R (R Core Team, Vienna, Austria), and data for all patients were collected in IBM SPSS Statistics 29.

Results

We present 32 novel patients (16 M/16 W) with an average age of 9.97 years (2-20 years). All individuals harbor variants affecting *USP7* (two whole-gene deletions, three partial gene deletions, one intragenic deletion, six truncating variants, 15 missense variants, and five splice-site variants) (*Table 1*). Figure 1 illustrates the distribution of missense and nonsense variants, revealing an enrichment of missense variants within the catalytic domain. Notably, no N-terminal nonsense variants were reported. The symptom reported most frequently is motor developmental delay, reflected by an overall delay in attainment of developmental milestones, followed by motor impairment, gait abnormalities, and muscular hypotonia. Furthermore, autism spectrum disorder (ASD), communication deficits, an abnormal pain threshold, gastrointestinal issues, and brain MRI anomalies are typical features presented by

157 more than two-thirds of the cohort analyzed in this study. A summary of the most frequent
158 symptoms is provided in *Table 2*, and a deeper analysis of all assessed symptoms subdivided
159 by genotype can be found in the supplemental material (*Supplemental Tables 1-13*).
160
161 *Growth parameters*
162 Growth parameters from 39 patients indicate a trend towards increased height, weight, and
163 BMI, with BMI achieving a statistically significant level (one sample t test; p_{BMI}= 0,0377).
164 Among the entire cohort, the mean weight measures at the 59th centile, the mean body
165 height measures at the 60th centile, and the mean BMI (18.84) lies within the 61st centile
166 (*Figure 1, Table 3*). For 34 total cases, we could analyze an age-adjusted BMI percentile. One
167 case is below the 5th centile indicating underweight as defined by the CDC[15], 22 cases are in
168 the average weight range, six fall in the overweight range, and five fulfill obesity criteria.
169 Therefore, 32 % of our entire cohort are overweight or obese. Although there is no general
170 trend towards growth retardation, 13 % (6/48) of this patient cohort indicate short stature,
171 defined as a body size at least two standard deviations below an age-adjusted standard
172 population[16]. Furthermore, 14 of 43 (33 %) patients showed small hands, while 19 of 46 (41
173 %) showed small feet, in both cases defined as feet and hand length below the age-adjusted
174 25th percentile (for novel cases).
175
176 *Pregnancy and birth*
177 Contrary to the body measurements described above, patients demonstrated a trend
178 towards reduced birth weight and body size. Average birth weight is at the 42nd centile, and
179 mean birth size at the 47th (*Figure 1, Table 3).* Neither sex nor genotype appear to influence
180 growth parameters or birth body measurements (*Supplemental Figures 1-3*). Interestingly,
181 we see both a subgroup being small for gestational age (birth weight below the 10th centile)
182 and one being large for gestational age (birth weight above the 90th centile). The former
183 criterion is met in 8 of 37 cases (22 %), the latter in six of 37 cases (16 %).
184 Neonatal muscular hypotonia affected a majority of 25 out of 44 individuals (57 %). Head
185 circumference measures at the gestational age-adjusted 47th centile and does not indicate
186 altered head circumference at birth. A single patient (3%) manifested hydrocephalus as an
187 infant. Twenty of 38 parents surveyed (53%) reported problems during pregnancy, which
188 ranged from common pregnancy-related issues such as gestational diabetes to detected
189 cardiac peculiarities or polyhydramnios. Decreased fetal movement was reported in seven of
190 44 cases (16 %). While preterm delivery occurred in eight of 40 cases (20 %), the mean
191 gestational age was 37.77 weeks. 15 of 37 parents (41 %) reported complications after
192 delivery and described those in a free-text answer, at which temperature instability was
193 named most often (five times), followed by severe jaundice (four times) and respiratory
194 distress (three times). Described congenital malformations met the criteria of having
195 significant medical, social, or cosmetic consequences for the affected individual in 14 of 34
196 cases (41 %). After the first case of a HAFOUS patient with congenital anomalies was
197 described by Capra et al. in 2019, we can now add 12 more individuals presenting anomalies
198 of the cardiac system (four times), the motor system (3 times), dysmorphisms of the head (3

times), malformation of the oral cavity or pharynx (3 times), and one patient born with a duplex pelvicalyceal system in the right kidney.

Given the disparities between current body measurements and those taken at birth, our aim was to explore the potential positive correlation between age and body weight, height, and BMI. Surprisingly, we observed a noteworthy decline in body weight and BMI percentiles as age increased (Supplemental Figure 4, A-C). Nevertheless, in our cohort and in line with the general population, absolute BMI values exhibit a positive correlation with age (Supplemental Figure 4D).

Developmental milestones

According to WHO data, the first motor development milestone, "sitting without support," is reached after 6.0 months, while "hand-and-knees crawling" is reached after 8.5 months, and "walking alone" can be accomplished after 12.1 months of life in the general population[17]. Presenting a delay at every motor development milestone, the cohort described here reached free sitting on average after 11.7 months, crawling after 14.3 months, and free walking after 26.6 months (*Table 3*). Twenty-six of 46 patients reached unsupported sitting after more than 9.2 months, 14/27 patients reached crawling after more than 13.5 months, and 39/47 patients reached free walking after more than 17.6 months. Each of these mentioned time points represents the respective 99th centile in the general population.

Regarding speech developmental milestones, children are expected to speak their first word at 18 months and can build the first two-words sentences 24 months after birth[18]. The cohort described here spoke their first words on average after 21.1 months and built their first two-word sentence after 32.9 months (*Table 3*). In this study, the oldest patient being nonverbal was 14 years old and can also not safely walk without support (#43), while Fountain et al. have already described a 20-year-old patient as nonverbal.

Intellectual ability

Fifteen families provided intellectual testing reports, which featured a full-scale intelligence quotient in 10 cases and a description of severe ID in two cases (WISC or WPPSI testing procedures). The mean FSIQ for this cohort is 78.3 (*Table 3*) and falls within the range of borderline intellectual functioning. Nonetheless, two of 12 patients present an IQ below 35, which defines severe intellectual disability (ID). Four of 12 patients score between 50 and 69, indicating mild ID, two of 12 patients score between 70 and 85, indicating borderline intellectual functioning, and another four patients show normal intellectual functioning with an IQ above 85. The highest IQ measured in this cohort is 105. Two previously described patients scored in the range of moderate ID [11,12].

According to previously published data, an extensive chart and questionnaire review revealed signs of intellectual disability or (a history of) developmental delay in all cases.

242 *Behavioral characteristics*
243 Behavioral characteristics were stated to be a defining feature of HAFOUS and, therefore,
244 also queried meticulously in this study. Testing for autism spectrum disorder was conducted
245 in 15 cases, leading to a diagnosis in 10 cases (67 %). To overcome a selection bias, parents
246 were also asked to state whether their child showed autistic features. Thirty-one parents
247 reported positive testing or autistic behavioral features (72 %), while 12 neither tested
248 positive nor showed behavioral features indicative of autism. ASD is more prevalent than
249 initially expected in HAFOUS. Five of 21 parents reported an improvement of the autistic
250 features over time, eight of 21 saw a worsening, and eight of 21 could not observe any
251 change.
252 Nine of 42 reported an attention deficit hyperactivity disorder (ADHD) diagnosis (21 %),
253 another 12 of 42 described ADHD-like behavioral traits, but lack of a formal diagnosis (29 %),
254 and 21 of 42 did not observe any feature reminiscent of ADHD.
255 Previous publications indicated manifold behavioral traits, including aggressive behavior,
256 temper tantrums, impulsivity, compulsivity, stubbornness, and manipulative behavior.
257 Improving the objectivity of this assessment, we collected answers on a *Likert scale* for
258 different behavioral traits, which would typically not be expected to appear often. Defined
259 between 1 indicating "always" and five indicating "never", the scores ranged from 4.18
260 ("destructive in her/his room") to 2.46 ("stubbornness"). Next to the latter, "impulsivity",
261 "overly social", and "physical contact seeking" scored values closer to always than never.
262 Previously described features like "aggressiveness" or "manipulative behavior" scored 3.46
263 and 3.95, respectively (*supplemental figure 5*). Therefore, we can only partially confirm the
264 previously described behavioral anomalies.
265 Furthermore, 10 of 29 parents reported general behavioral problems (34 %), 16 of 31
266 patients showed obsessive-compulsive behavior (52 %), and only 9 of 52 parents observed
267 skin picking (17 %).
268
269 *Musculoskeletal phenotype*
270 One of the most frequent symptoms of HAFOUS is hypotonia, prevalent in 42 of 53 patients
271 (79 %). Hypotonia improved over time in the vast majority of 23 out of 30 cases (worsened in
272 two cases, no change in 5 cases). This is surprising, given that hypotonia at the time of
273 examination is more prevalent than neonatal hypotonia, indicating a numerical increase of
274 cases, although the individual courses may be ameliorating on average. Aside from low
275 muscle tone, other dysfunctions of the muscular system can be observed. Abnormal gait was
276 reported in 31 of 47 individuals (66 %), and 23 of 35 exhibit balance unsteadiness (66 %).
277 Motor dysfunction affects all categories and is indicated by fine motor delay/impairment
278 (25/37, 68 %), gross motor delay/impairment (29/39, 74 %), as well as oral motor skills
279 delay/impairment (29/39, 76 %).
280 Less prevalent are scoliosis/kyphosis, which can be seen in 14 of 47 patients (30 %), and joint
281 contractures, reported by 11 of 45 affected families (24 %), most frequently located at the
282 lower extremity (6 cases).

283 Diverse dental issues were described by 20 of 36 parents (56 %), and the severity of the
284 issues ranges from severe malformations to cosmetic conspicuities. "Large front teeth" were
285 reported five times, while "deep palatal vault" and "supernumerary teeth" were reported
286 three times, respectively. Seventeen more issues were described no more than one time.
287
288 *Neurological/ ophthalmological features*
289 Eye anomalies were previously reported to affect a vast majority of HAFOUS patients. We
290 can confirm this for 28 of 53 patients in this cohort (53 %) and found farsightedness (10/34,
291 27 %) to appear most frequently (*supplemental table 5*).
292 One of the queried items proposed by the foundation was an abnormal pain threshold, a
293 known symptom of PWS[19]. We saw a high threshold for pain at 19 of 34 (56 %) patients and
294 a low threshold for pain at another seven of 34 (21%) patients, indicating 76 % with a
295 parent-reported dysfunctional pain threshold.
296 Although delayed speech development was described for HAFOUS previously and is
297 confirmed here, speech abilities at a later stage have never been described. 24 of 37 (65 %)
298 parents reported limited communication skills, being reflected both by reduced expressive
299 (26/38, 68 %) and receptive (23/36, 64 %) communication. Furthermore, parents were asked
300 which feature would be the most disabling symptom of their children and in 16 of all 38
301 questionnaires, parents reported speech problems as the most disabling feature,
302 highlighting the significance of this deficit for the affected individuals (cognitive impairment
303 named nine times, behavioral anomalies named eight times).
304 Hearing difficulties were reported in nine of 51 (18%) cases, and temperature instability was
305 reported in 14 of 34 (41 %) patients.
306 Fountain et al. extensively analyzed brain MRI reports in 2019, and we can mainly confirm
307 their findings based on the 13 new reports received. Combined with previously published
308 reports, brain MRIs exhibit anomalies of the ventricular system in 12 of 25 cases, signs of
309 white matter paucity/ small corpus callosum in 11/25 cases, simplified gyral patterns in 4/25
310 cases, white matter hyperintensities in 3/25 cases, vermian atrophy in 3/25 cases, and
311 hippocampal anomaly as well as a thick corpus callosum one time respectively. Summarizing
312 the reports, 23 of 34 (68 %) patients show any sign of abnormality described in their brain
313 MRI report with a wide variety of clinical significance as described above.
314
315 *Seizures and sleep*
316 Sleep disturbances were reported for 22 of 47 (47 %) patients and could partially explain the
317 frequent occurrence of fatigue (26/37, 70%) and a great need for rest (23/36, 64%). Sleep
318 apnea occurs in 10 of 34 (29 %) individuals.
319 Seizures were previously stated as a very prevalent and characteristic feature of HAFOUS. 23
320 of 57 (40 %) patients in the cohort described here were affected by seizures or have a history
321 of seizures; most effectively treated with anti-epileptic medications. The highest frequency
322 of seizures reported is 14 per year. Three of 32 (9 %) individuals had a febrile seizure. In
323 most cases, the reason for the seizures could not be clarified. Three of 19 (16 %) EEG reports
324 we received showed anomalies, in all three cases describing (probable) epileptic potential.

Ten parents provided information about the course of this symptom, and while four did not observe any difference, six families confirmed an improvement concerning seizures over time.

Gastrointestinal features

This cohort's most frequent gastrointestinal issues are constipation or diarrhea, affecting 29 of 52 (56 %) patients. Incontinence inappropriate for the individual's age was reported by 15 of 38 (39 %) parents. Gastroesophageal reflux disease can be observed in 18 of 49 (37 %) cases, and five of 35 (14 %) parents reported jaundice beyond the neonatal period. In four of 38 (10 %) cases, gastrointestinal issues were described as the most disabling symptom.

Eating behavior

Abnormal eating behavior is one of the key features of PWS and, therefore, also of great interest in HAFOUS research. 30 out of 54 individuals (56 %) in the cohort here experienced feeding difficulties during infancy, closely associated with 15 of 51 (29 %) patients having difficulties gaining weight. Eating difficulties can be observed in 16 of 36 (44 %) cases. For the first time, we describe 14 of 36 (39 %) HAFOUS patients presenting hyperphagia. While this parental assessment lacks objectivity, further behavioral characteristics like mouthing behavior (10/34, 29 %) and chewing of inedible objects (10/37, 27 %) support this finding. Furthermore, 23 % (3/13) of the children showing hyperphagia are obese, while only 5 % (1/20) fulfill this criterion in the non-hyperphagic group. Manifestation of hyperphagia began three times in the neonatal period (first month of life), four times in infancy (second month until the end of the second year), five times in early childhood (three until eight years), and once later than that.

Further physical characteristics

We also asked for endocrinological and respiratory dysfunction but could not identify any features of high prevalence.

Hypothyroidism (1/21, 5 %), adrenal insufficiency (1/21, 5 %), and growth (GH) deficiency (2/24, 8 %) were reported in only few patients, while hypogonadism was observed in 11 of 47 patients (23 %). We also included 4 of 16 boys with cryptorchidism/ micropenis.

Only a few patients depended on respiratory assistance in the form of intubation (2/35, 6 %) or mechanical ventilation (3/35, 9 %). In 2 of 3 cases, chart review revealed that ventilation was necessary immediately postnatally, while the context could not be outlined for one further case. Asthma was prevalent in 8 of 36 (22 %) patients.

Eczema was described by 12 of 34 (35 %) parents.

Genotype-phenotype association

The cause of clinical heterogeneity in *USP7*-related disorder is not very well understood. Aiming to overcome this issue, a severity score was developed as described before (methods, supplemental methods). Anderson-Darling test ($p=0.4699$), Shapiro-Wilk test ($p=0.3424$), and Kolmogorov-Smirnov test ($p>0.1$) were passed. Therefore, normal

366 distribution can be assumed (*supplemental figure 6A*). The mean severity score is 0.4937
367 (SD: 0.1561) for the 38 values we generated.
368 To better understand influencing factors on the severity, we compared both sexes and found
369 no difference (M: 0.49 SD 0.14, n:16; W: 0.50 SD 0.17, n:22) (*figure 2A).* Furthermore, age
370 and type of the underlying genotype do not influence severity significantly (DEL: 0.47 SD
371 0.13, NON: 0.41 SD 0.12, MISS: 0.53 SD 0.18, SPLIC: 0.49 SD 0.07) (*figure 2B, supplemental*
372 *figure 6B*). Due to the heterogeneity of severity within the group harboring missense
373 variants, a correlation of exact position of the mutation and severity was investigated.
374 Missense mutations were grouped based on functionally relevant protein regions. A mean
375 value of 0.64 (n: 10) was found for the catalytic domain, 0.48 (n: 2) for the TRAF-like domain,
376 and 0.41 (n: 8) for the UBL-like domain, reflecting a significantly increased severity score for
377 mutations affecting the catalytic domain of USP7 (figure 2C, p = 0.0041).
378 Furthermore, to assess the predicted effect of missense variants, commonly used prediction
379 scores (CADD v1.6, M-CAP v.3.5a, REVEL v.3.5a21-23) were annotated for all biologically
380 possible USP7 missense variants and mapped onto a linearized representation of the USP7
381 protein, as previously demonstrated[20]. A generalized additive model was built using the
382 geom_smooth function of the R (R Core Team, Vienna, Austria) ggplot2 package to plot a
383 smoothened line and confidence interval (Supplemental Figure 7). Violin plots of
384 pathogenicity scores associated with all biologically possible missense variants falling into
385 either the catalytic domain, the TRAF-like domain or one of five Ubiquitin-like domains were
386 generated. Missense variants in catalytic domain are associated with statistically significant
387 higher pathogenicity scores shown by the assessment of three individual scores (REVEL,
388 MCAP, and CADD score) (Supplemental Figure 8).
389
390 **Discussion**
391 HAFOUS is a neurodevelopmental disorder leading to a variable clinical spectrum in terms of
392 occurrence and severity of symptoms. Speech and motor delay are most prevalent. Patients
393 typically present with communication deficits, muscular hypotonia, motor issues, abnormal
394 threshold for pain, and autism spectrum disorder. Complications during birth and congenital
395 anomalies are frequently present. Further symptoms such as seizures, hyperphagia, or
396 scoliosis only affect a subset of individuals. As previously proposed, this disorder can be
397 considered part of a disease family with SYS and PWS[21], showing a wide overlap of
398 symptoms between these disorders and a hypothesized shared path of pathophysiology via
399 the MUST complex[22]. Developmental delay, muscular hypotonia, reduced birth weight, and
400 infant feeding difficulties are shared features among these disorders[5,7].
401 Furthermore, endocrine dysfunction, also described as hypothalamic insufficiency, is a
402 crucial feature of SYS and PWS, but could not be seen frequently in our cohort[23,24]. ASD is
403 much more prevalent in HAFOUS and SYS (72 % and 78 %) compared to PWS (27 %)[7,25]. SYS,
404 with its unique prevalence of joint contractures and respiratory dysfunctions accompanied
405 by the most severe manifestation of developmental delay, intellectual disability, and
406 increased mortality, can be considered the most severe disorder within this disease family[7].
407 The causative factors need to be further investigated, but a neomorphic function of the

408 truncated MAGEL2 protein or a suppression of leaky expression from the maternal allele at
409 SYS was previously hypothesized to contribute to the alteration of manifestation between
410 these disorders[22]. HAFOUS positions itself as the least severe manifestation within this
411 disease family due to milder developmental delay, higher intellectual functioning, and
412 mostly an absence of endocrine dysfunctions (see[7,26,27]). Considering the MUST pathway as
413 one of the driving factors of these diseases, it is noteworthy to mention that pathogenic
414 variants in *USP7* were reported only heterozygous, suggesting the presence of wild-type and
415 variant USP7 proteins, while MAGEL2 mutations associated with PWS and SYS are
416 functionally hemizygous, suggesting the complete absence of wild-type MAGEL2. Therefore,
417 it can be presumed that mutations underlying SYS or PWS have a greater impact on the
418 functionality of the MUST complex than mutations causing HAFOUS. Nevertheless, the
419 variability of symptoms is intriguing, and some patients face a much more severe phenotype
420 than others. Although we provide data indicating the most severe phenotypes in patients
421 with missense variants within the catalytic domain, predicting the severity of phenotypes
422 based on individual mutations remains challenging.
423
424 This work sheds light on new, previously undescribed features of HAFOUS. Most remarkably,
425 we found an abnormal threshold for pain affecting 76 % of the cohort. Furthermore, we
426 describe some individuals presenting hyperphagia and potentially associated obesity.
427 Complications during pregnancy and congenital anomalies of varying severity had not been
428 reported previously. In addition to describing symptoms for the first time, we provide more
429 profound data for all previously described symptoms and observe a higher prevalence of
430 ASD than indicated by previous studies. Some features like seizures and particularly
431 aggressive and impulsive behavior are not as prevalent as initially hypothesized.
432 Developmental anomalies manifest in a variable trajectory of body weight, height, and BMI.
433 In contrast to the general population, we note slightly diminished birth height and weight,
434 with current body measurements reflecting a modest increase. However, there is a
435 discernible decrease in BMI and body weight with advancing age, suggesting an irregular and
436 atypical pattern of body growth.
437
438 Most significantly, we also analyzed genotype-phenotype correlations based on a developed
439 severity score and found increased severity scores for patients with a missense mutation
440 inside the catalytic domain of *USP7*, compared to those with a mutation outside the catalytic
441 domain. Evaluation of in silico scores revealed significant higher pathogenicity scores if
442 missense mutations occurred in the catalytic domain. Based on these results, we
443 hypothesize that missense variants within the catalytic domain of the protein are associated
444 with a more severe clinical phenotype compared to variants in the other parts of the protein.
445 We recommend analyzing larger cohorts even in the initial phase of investigating a novel
446 disease to ensure a reliable foundation of data. Our approach to include the disease
447 community when creating the questionnaire, appears helpful for gathering data on
448 previously undescribed features.

TRIM27 is another component of the MUST-complex and was not previously described in case reports or systematic patient cohort analyses of neurodevelopmental disorders. This is surprising as other proteins of this pathway can be assigned to various neurodevelopmental conditions[22]. We currently aim to identify individuals carrying *TRIM27* variants to provide a systematic analysis.

Interestingly, a recent paper implicates all the variable functions of USP7, but especially contribution of USP7 to epigenetic transcriptional regulation, in the search for an etiology of HAFOUS[28]. This seems reasonable to us as this group revealed that USP7 is highly associated with histone ubiquitination on a transcriptional and posttranslational level as a silencer or stabilizing partner for relevant factors of the PRC1 complex and therefore contributes to the expression of several neurodevelopmental factors like AUTS2[28]. Establishing animal models of this disorder could help understand the exact mechanism of pathophysiology and the cellular pathways contributing to the phenotype. Remarkably, an overexpression mouse model of *Usp7* presented altered dendritic arborization, neuronal migration, a behavioral phenotype, and altered pain threshold, which is partially reminiscent of the phenotype observed in our cohort suggesting dosage-sensitivity of Usp7 during neurodevelopment[29].

This study is subject to some limitations. The symptoms were recorded in a questionnaire by interviewing the parents and are thus primarily subjective. Whenever possible, clinical charts and records were assessed to ensure objectivity. Furthermore, the developed severity score is limited by a detection bias, meaning that the objective nature of such scores always limits the possible coverage of symptoms and individuality.

A phenotyping study of individuals at the University Hospital of Heidelberg is currently being conducted to overcome this issue. By analyzing 32 novel and six previously described patients, this study helps understand the clinical spectrum of HAFOUS, reveals undescribed symptoms, and provides a first approach to a genotype-phenotype correlation. With this, we intend to contribute to a more reliable and sound genetic consulting and prediction of phenotype for affected individuals and families.

477 **5 References**

478

479 1. Valles GJ, Bezsonova I, Woodgate R, Ashton NW. USP7 Is a Master Regulator of
480 Genome Stability. *Front Cell Dev Biol*. 2020;8:717. doi:10.3389/fcell.2020.00717
481 2. Hao YH, Doyle JM, Ramanathan S, et al. Regulation of WASH-dependent actin
482 polymerization and protein trafficking by ubiquitination. *Cell*. Feb 28 2013;152(5):1051-64.
483 doi:10.1016/j.cell.2013.01.051
484 3. Hao YH, Fountain MD, Jr., Fon Tacer K, et al. USP7 Acts as a Molecular Rheostat to
485 Promote WASH-Dependent Endosomal Protein Recycling and Is Mutated in a Human
486 Neurodevelopmental Disorder. *Mol Cell*. Sep 17 2015;59(6):956-69.
487 doi:10.1016/j.molcel.2015.07.033
488 4. Schaaf CP, Gonzalez-Garay ML, Xia F, et al. Truncating mutations of MAGEL2 cause
489 Prader-Willi phenotypes and autism. *Nat Genet*. Nov 2013;45(11):1405-8.
490 doi:10.1038/ng.2776
491 5. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. *Genet Med*. Jan
492 2012;14(1):10-26. doi:10.1038/gim.0b013e31822bead0
493 6. Fountain MD, Oleson DS, Rech ME, et al. Pathogenic variants in USP7 cause a
494 neurodevelopmental disorder with speech delays, altered behavior, and neurologic
495 anomalies. *Genet Med*. Aug 2019;21(8):1797-1807. doi:10.1038/s41436-019-0433-1
496 7. McCarthy J, Lupo PJ, Kovar E, et al. Schaaf-Yang syndrome overview: Report of 78
497 individuals. *Am J Med Genet A*. Dec 2018;176(12):2564-2574. doi:10.1002/ajmg.a.40650
498 8. Fountain MD, Aten E, Cho MT, et al. The phenotypic spectrum of Schaaf-Yang
499 syndrome: 18 new affected individuals from 14 families. *Genet Med*. Jan 2017;19(1):45-52.
500 doi:10.1038/gim.2016.53
501 9. Castilla-Vallmanya L, Centeno-Pla M, Serrano M, et al. Advancing in Schaaf-Yang
502 syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2. *J*
503 *Med Genet*. Sep 7 2022;doi:10.1136/jmg-2022-108690
504 10. Capra AP, Agolini E, La Rosa MA, Novelli A, Briuglia S. Correspondence on "Pathogenic
505 variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior,
506 and neurologic anomalies" by Fountain et al. *Genet Med*. Feb 2021;23(2):421-422.
507 doi:10.1038/s41436-020-00978-x
508 11. Priolo M, Mancini C, Pizzi S, et al. Complex Presentation of Hao-Fountain Syndrome
509 Solved by Exome Sequencing Highlighting Co-Occurring Genomic Variants. *Genes (Basel)*.
510 May 16 2022;13(5)doi:10.3390/genes13050889
511 12. Zampieri N, Pulvirenti R, Pedrazzoli E, Camoglio FS. Hao-Fountain syndrome and
512 genital disorders: report of a new possible association. *Ital J Pediatr*. Oct 22 2022;48(1):182.
513 doi:10.1186/s13052-022-01367-7
514 13. Zheng H, Mei S, Li F, et al. Expansion of the mutation spectrum and phenotype of
515 USP7-related neurodevelopmental disorder. *Front Mol Neurosci*. 2022;15:970649.
516 doi:10.3389/fnmol.2022.970649
517 14. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of
518 sequence variants: a joint consensus recommendation of the American College of Medical
519 Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. May
520 2015;17(5):405-24. doi:10.1038/gim.2015.30
521 15. Skinner AC, Perrin EM, Skelton JA. Prevalence of obesity and severe obesity in US
522 children, 1999-2014. *Obesity (Silver Spring)*. May 2016;24(5):1116-23.
523 doi:10.1002/oby.21497

16. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P, International Small for Gestational Age Advisory B. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. *Pediatrics*. Jun 2003;111(6 Pt 1):1253-61. doi:10.1542/peds.111.6.1253
17. Group WHOMGRS. WHO Motor Development Study: windows of achievement for six gross motor development milestones. *Acta Paediatr Suppl*. Apr 2006;450:86-95. doi:10.1111/j.1651-2227.2006.tb02379.x
18. Dosman CF, Andrews D, Goulden KJ. Evidence-based milestone ages as a framework for developmental surveillance. *Paediatr Child Health*. Dec 2012;17(10):561-8. doi:10.1093/pch/17.10.561
19. Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. *Curr Pediatr Rev*. 2019;15(4):207-244. doi:10.2174/1573396315666190716120925
20. Schroter J, Dattner T, Hullein J, et al. aRgus: Multilevel visualization of non-synonymous single nucleotide variants & advanced pathogenicity score modeling for genetic vulnerability assessment. *Comput Struct Biotechnol J*. 2023;21:1077-1083. doi:10.1016/j.csbj.2023.01.027
21. Marbach F, Schaaf CP. Response to Briuglia et al. *Genet Med*. Feb 2021;23(2):423-424. doi:10.1038/s41436-020-00977-y
22. Fountain MD, Schaaf CP. Prader-Willi Syndrome and Schaaf-Yang Syndrome: Neurodevelopmental Diseases Intersecting at the MAGEL2 Gene. *Diseases*. Jan 13 2016;4(1)doi:10.3390/diseases4010002
23. McCarthy JM, McCann-Crosby BM, Rech ME, et al. Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome. *J Med Genet*. May 2018;55(5):307-315. doi:10.1136/jmedgenet-2017-105024
24. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. *J Endocrinol Invest*. Dec 2015;38(12):1249-63. doi:10.1007/s40618-015-0312-9
25. Bennett JA, Germani T, Haqq AM, Zwaigenbaum L. Autism spectrum disorder in Prader-Willi syndrome: A systematic review. *Am J Med Genet A*. Dec 2015;167A(12):2936-44. doi:10.1002/ajmg.a.37286
26. Thomason MM, McCarthy J, Goin-Kochel RP, Dowell LR, Schaaf CP, Berry LN. Neurocognitive and Neurobehavioral Phenotype of Youth with Schaaf-Yang Syndrome. *J Autism Dev Disord*. Jul 2020;50(7):2491-2500. doi:10.1007/s10803-018-3775-7
27. Curfs LM, Fryns JP. Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile. *Birth Defects Orig Artic Ser*. 1992;28(1):99-104.
28. Sijm A, Atlasi Y, van der Knaap JA, et al. USP7 regulates the ncPRC1 Polycomb axis to stimulate genomic H2AK119ub1 deposition uncoupled from H3K27me3. *Sci Adv*. Nov 4 2022;8(44):eabq7598. doi:10.1126/sciadv.abq7598
29. Qiao H, Tian Y, Huo Y, Man HY. Role of the DUB enzyme USP7 in dendritic arborization, neuronal migration, and autistic-like behaviors in mice. *iScience*. Jul 15 2022;25(7):104595. doi:10.1016/j.isci.2022.104595

572 **7 Legends**
573
574 **Figure 1**: Distribution of USP7 missense and nonsense variant
575 The known domains and the distribution of missense/nonsense variants along a two-
576 dimensional representation of the USP7 protein are shown. The size of the points of the
577 missense variants correlate with the respective REVEL score.
578
579 **Figure 2**: Body measurements of patients with Hao-Fountain Syndrome; one sample t-test
580 performed for a mean value of 50
581 A: BMI subdivided by normal weight, overweight, obesity; B: Current measurement
582 percentiles; C: Birth measurement percentiles
583
584 **Figure 3**: Assessment of severity score values in variable subgroups; Student's t-test and one-
585 way ANOVA
586 A: Severity score plotted for sex.; B: Severity score for each type of mutation.; C: Severity
587 score of missense mutations grouped by localization (Catalytic domain vs. TRAF-like- and
588 UBL-domain).
589
590
591 **Table 1** Novel cases with pathogenic USP7 variants
592
593 **Table 2** Summary of published and novel cases with pathogenic USP7 variants
594
595 **Table 3** Developmental/ speech milestones, growth parameters, and IQ of patients with
596 Hao-Fountain Syndrome
597
598
599 **Supplemental figure 1:** Body measurements compared by sex
600 A: BMI values (Student's t-test).; B: Current body measurement percentiles; C: Birth body
601 measurement percentiles
602
603 **Supplemental figure 2:** Current body measurements compared by genotype
604 A: BMI values (One-way ANOVA); B: Current body length percentile (One-way ANOVA); C:
605 Current body weight percentile (One-way ANOVA); D: BMI percentile (One-way ANOVA)
606
607 **Supplemental figure 3:** Birth body measurements compared by sex and genotype
608 A: Birth body weight percentiles (One-way ANOVA); B: Birth head circumference percentiles
609 (One-way ANOVA); C: Birth body length percentiles (One-way ANOVA); D: Birth
610 measurements compared by sex
611
612 **Supplemental figure 4:** Body measurements plotted against age indicating a significant
613 impact of age on weight percentile (B), BMI percentile (C), and BMI values (C)

614
615 **Supplemental figure 5**: Behavioral traits of Hao-Fountain syndrome patients
616 Several behavioral traits and parental-reported frequency of occurrence ranging from 5
617 (Always) to 1 (Never) (n: 36).
618
619 **Supplemental Figure 6:** Severity score QQ plot and assessment for different subgroups
620 A: QQ plot proofing normal distribution of severity scores within our cohort; B: Severity
621 score plotted against age of individuals (slope: 0,0004920) indicating no impact of age on
622 severity; C: Severity score of patients with a truncating mutation plotted for the location of
623 the predicted location of the truncation; D: Severity score of patients with a missense
624 mutation plotted for the location of the predicted location of the truncation (Tukey's
625 multiple comparison test following one-way ANOVA; CD vs. UBL: adjusted p-value = 0.0131)
626
627 **Supplemental Figure 7**: Comparison of three pathogenicity score predictions
628
629 **Supplemental Figure 8:** Statistical comparison of domain-associated pathogenicity scores
630
631 **Supplemental table 1 – Molecular phenotype**: Comprehensive molecular phenotype
632 information on known patients with HAFOUS, including variant coordinates, inheritance, and
633 mutational group allocation, in silico scores, and AMP/ACMG re-classification (all based on
634 NM_003470.3). Novel cases identified as individuals #30-#61.
635
636 **Supplemental table 2 – Behavioral and cognitive profile**: Behavioral phenotypical aspects of
637 all known individuals with HAFOUS, also containing information about cognition (sorted by
638 mutation type).
639
640 **Supplemental table 3 – Motor + speech development**: Milestones in motor and speech
641 development for HAFOUS patients, categorized by mutation type.
642
643 **Supplemental table 4 – Musculoskeletal phenotype**: Musculoskeletal phenotypic features
644 observed in HAFOUS patients, categorized by mutation type.
645
646 **Supplemental table 5 – Neurological phenotype**: Neurological manifestations in HAFOUS
647 patients, sorted by mutation type.
648
649 **Supplemental table 6 – Endocrine phenotype**: Detailed endocrine phenotype of HAFOUS
650 patients, sorted by mutation type.
651
652 **Supplemental table 7 – Respiratory phenotype**: Respiratory phenotype in HAFOUS patients,
653 categorized by mutation type.
654
655 **Supplemental table 8 – Sleep + seizures + EEG**: Sleep patterns, EEG study results, and
656 seizure occurrences in HAFOUS patients, sorted by mutation type.
657

Supplemental table 9 – Eating behavior: Parental-reported eating behavior of all known individuals with HAFOUS, sorted by mutation type.

Supplemental table 10 – Gastrointestinal phenotype: Gastrointestinal phenotypes in HAFOUS patients, categorized by mutation type.

Supplemental table 11 – Body measurements: Comprehensive body measurements of HAFOUS patients, sorted by mutation type.

Supplemental table 12 – Birth and neonatal period: Phenotypic aspects of the birth and neonatal period in HAFOUS patients, categorized by mutation type.

Supplemental table 13 – More phenotypical aspects: Further phenotypical aspects of HAFOUS patients, sorted by type of mutation. Also containing parental-reported symptoms not being listed in our questionnaire and parental-identified aspects being “most disabling” and “the most striking capability”.

Supplemental table 14 – Severity score: Calculation of severity scores for HAFOUS patients meeting missense or truncating mutation criteria within our cohort. Includes points per category, cumulative points, maximum achievable points, and severity scores per individual.

Figures



Figure 1: Distribution of *USP7* missense and nonsense variants.
The known domains and the distribution of missense/nonsense variants along a two-dimensional representation of the USP7 protein are shown. The size of the points of the missense variants correlates with the respective REVEL score.



Figure 2: Body measurements of individuals with Hao-Fountain Syndrome; one sample t-test performed for a mean value of 50.
A: BMI subdivided by normal weight, overweight, obesity; B: Current measurement centiles; C: Birth measurement centiles



Figure 3: Assessment of severity score values in variable subgroups; Student's t-test and one-way ANOVA.

A: Severity score plotted for sex; B: Severity score for each type of mutation.; C: Severity score of missense mutations grouped by localization (Catalytic domain vs. TRAF-like- and UBL-domain).

Table 1 Novel cases with pathogenic USP7 variants

Case number	Mutation coordinates	Predicted protein	Inheritance	Type of mutation
30[A]	g.8821978_9123395del		de novo	DEL
31	g.8949646_9109391del		de novo	DEL
32	g.8889561_9051816del		de novo	DEL
33	g.8822840_9053972del		de novo	DEL
34	g.9017053_9035103del		de novo	intragenic DEL
35	g.8915707_8925560del		de novo	intragenic DEL
36	c.238A>T	p.(Arg80*)	de novo	NON
37	c.1157T>A	p.(Leu386*)	de novo	NON
38	c.517dup	p.(Trp173Leufs*3)	de novo	Frameshifting indel
39	c. 786_787del	p.(Arg262Serfs*4)	de novo	Frameshifting indel
40	c.339_340del	p.(Ser114Argfs*10)	de novo	Frameshifting indel
41	c.1794dup	p.(Asn599Glufs*6)	de novo	Frameshifting indel
42	c.3043G>A	p.(Glu1015Lys)	de novo	MISS
43	c.650A>G	p.(Lys217Arg)	de novo	MISS
44[B]	c.3202G>C	p.(Gly1068Arg)	mother and siblings do not carry the mutation	MISS
45	c.1754A>T; c.1691A>C	p.(Asp585Val); p.(Glu564Ala)	de novo	MISS
46	c.3043G>A	p.(Glu1015Lys)	de novo	MISS
47	c.3147G>C	p.(Gln1049His)	unkown	MISS
48	c.841A>G	p.(Lys281Glu)	de novo	MISS
49[C]	c.1258A>G	p.(Lys420Glu)	de novo	MISS
50	c.352T>C	p.(Phe118Leu)	de novo	MISS
51	c.884A>G	p.(Asp295Gly)	de novo	MISS
52	c.490G>A	p.(Asp164Asn)	de novo	MISS
53	c.1175G>C	p.(Gly392Ala)	de novo	MISS
54	c.2021C>T	p.(Ala674Val)	de novo	MISS
55	c.1018C>T	p.(Arg340Trp)	unkown	MISS
56	c.1480A>G	p.(Ile494Val)	unkown	MISS
57[D]	c.2718+5G>A		de novo	SPLIC
58	c.2132_2140+9del		de novo	SPLIC

59	c.721-1G>C		de novo	SPLIC
60	c.1162-8A>G		de novo	SPLIC
61	c.1840-1G>A		de novo	SPLIC

All variants based on NM_003470.3 (hg19)

DEL = Deletion; NON = Nonsense mutation; MISS = Missense mutation; SPLIC = Splice-site mutation

[A]Patient also has a 326 kb duplication at 15a23 including MAP2K and SKOR1 (maternal variant of uncertain significance)

[B]Patient also has a VUS in SIX3, loss of function variants in this gene associated with nonsyndromic holoprosencephaly were described

[C]Patient also has a likely pathogenic variant in TCF20

Table 2 Summary of published and novel cases with pathogenic USP7 variants

Clinical feature	Literature	Our study	Summary	
Muscular hypotonia	16/23	26/30	*42/53*	**79 %**
Oral motor skills delayed/ impaired	6/7	23/31	*29/38*	**76 %**
Altered threshold for pain	6/6	20/28	*26/34*	**76 %**
Gross motor skills delayed/ impaired	6/7	23/32	*29/39*	**74 %**
ASD	14/18	17/25	*31/43*	**72 %**
Fine motor skills delayed/ impaired	5/6	20/31	*25/37*	**68 %**
Brain MRI anomalies	26/21	7/13	*23/34*	**68 %**
Abnormal gait	8/17	23/30	*31/47*	**66 %**
Limited communication skills	2/6	22/31	*24/37*	**65 %**
Neonatal hypotonia	10/20	15/24	*25/44*	**57 %**
Dental issues	4/6	16/30	*20/36*	**56 %**
Feeding difficulties	14/22	16/32	*30/54*	**56 %**
Chronic constipation/ diarrhea	14/20	15/32	*29/52*	**56 %**
Eye anomalies	17/25	11/28	*28/53*	**53 %**
Complications during pregnancy	3/8	17/30	*20/38*	**53 %**
ADHD	7/17	14/25	*21/42*	**50 %**
Sleep disturbances	7/18	15/29	*22/47*	**47 %**
Eating difficulties	4/7	12/29	*12/36*	**44 %**
Temperature instabilities	2/4	12/30	*14/34*	**41 %**
Small feet	7/21	12/25	*19/46*	**41 %**
Complications during delivery	2/6	13/31	*15/37*	**41 %**
Congenital anomalies	2/5	12/29	*14/34*	**41 %**
Seizures	13/27	10/30	*23/57*	**40 %**
Neonatal poor suck	6/19	14/31	*20/50*	**40 %**
Hyperphagia	1/5	13/31	*14/36*	**39 %**
Incontinence	3/6	12/32	*15/38*	**39 %**
GERD	10/19	8/30	*18/49*	**37 %**
Behavioral problems	2/5	8/24	*10/29*	**34 %**
Small hands	8/21	6/22	*14/43*	**33 %**
Scoliosis/ Kyphosis	7/20	7/27	*14/47*	**30 %**
Sleep apnea	2/6	8/28	*10/34*	**29 %**
Gaining weight difficulties	7/19	8/32	*15/51*	**29 %**
Contractures	7/19	4/26	*11/45*	**24 %**
Hypogonadism	7/19	4/28	*11/47*	**23 %**
SGA	4/7	4/29	*8/36*	**22 %**
EEG anomalies	1/5	3/15	*4/20*	**20 %**

Skin picking	4/22	5/30	*9/52*	**17 %**
LGA	0/7	6/29	*6/36*	**17 %**
Short stature	4/19	2/29	*6/48*	**13 %**
GH deficiency	2/4	0/20	*2/24*	**8 %**

Table 3 Developmental/ speech milestones, growth parameters, and IQ of patients with Hao-Fountain Syndrome

	Mean value	**Expected value (normal population)**	**Assessed individuals (*n*)**
First spoken word	**21,1** months	18 months	*30*
First combining words	**32,9** months	24 months	*24*
Sit w/o support	**11,7** months	6 months	*46*
Crawl	**14,3** months	12 months	*27*
Walk w/o support	**26,6** months	15 months	*47*
FSIQ	**78,30**	100	*10*
Body weight percentile	**58,35**	50	*39*
Body length percentile	**59,23**	50	*38*
BMI	**18,84**	depends on age	*36*
BMI percentile	**60,63**	50	*34*
Birth weight percentile	**41,19**	50	*36*
Birth length percentile	**46,67**	50	*38*